[Alveolar soft part sarcoma in pediatric patients]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Context:

• Alveolar soft part sarcoma (ASPS) is a rare malignant neoplasm.
• It predominantly affects adolescents and young adults, primarily in the limbs.
• ASPS exhibits a characteristic translocation t(X;17)(p11;25) leading to the ASPL-TFE3 fusion protein.

Purpose:

• To review the clinical manifestations, diagnosis, radiographic characteristics, and therapeutic strategies for ASPS in the pediatric population.
• To highlight the molecular underpinnings and indolent yet metastatic potential of ASPS.
• To discuss current and emerging treatment modalities for ASPS.

Summary:

• ASPS presents with an indolent clinical course but carries a high risk of pulmonary and cerebral metastases.
• Surgical resection is the primary treatment for localized disease; chemotherapy is often ineffective.
• Radiotherapy may reduce local recurrence but does not impact overall survival.
• Targeted therapies, including anti-angiogenic drugs and tyrosine kinase inhibitors, show promise but require further investigation.
• Prognostic factors include age, tumor size, and metastatic status, with 5-year survival around 80% for localized disease.

Impact:

• Provides a comprehensive overview of ASPS in pediatric patients for clinicians and researchers.
• Emphasizes the need for further research into targeted therapies for improved ASPS outcomes.
• Contributes to understanding the molecular basis and clinical behavior of this rare sarcoma.